Alx Oncology Holdings (ALXO) Share-based Compensation (2019 - 2026)
Alx Oncology Holdings (ALXO) posted Share-based Compensation of $2.5 million for Q1 2026, down 7.28% sequentially from $2.7 million in Q4 2025, and down 51.9% YoY from $5.2 million in Q1 2025.
Alx Oncology Holdings (ALXO) Share-based Compensation (2019 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Share-based Compensation for 8 years, with the latest figure at $2.5 million in Q1 2026.
- Quarterly Share-based Compensation fell 51.9% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (up 159.54% YoY) and the FY2025 annual result came in at $12.6 million, down 56.1% from the prior year.
- Share-based Compensation eased to $2.5 million in Q1 2026 per ALXO's latest filing, from $2.7 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $7.0 million in Q3 2023 and troughed at -$19.6 million in Q4 2024.
- A 5-year average of $1.0 million and a median of $861000.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation surged 3332.97% in 2023, then slumped 391.67% in 2024.
- Over 5 years, Share-based Compensation stood at -$4.1 million in 2022, then soared by 263.25% to $6.7 million in 2023, then slumped by 391.67% to -$19.6 million in 2024, then surged by 113.8% to $2.7 million in 2025, then fell by 7.28% to $2.5 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.5 million, $2.7 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Alx Oncology Holdings | 270.90 Mn | 270.90 Mn | - | 2.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.68 Mn |
| Jun 30, 2026 | 2.68 Mn |
| Mar 31, 2026 | 2.51 Mn |
| Mar 31, 2026 | 2.51 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Jun 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 5.22 Mn |
| Mar 31, 2025 | 5.22 Mn |
| Dec 31, 2024 | -19.60 Mn |
| Dec 31, 2024 | -19.60 Mn |
| Sep 30, 2024 | 534,000.00 |
| Sep 30, 2024 | 534,000.00 |
| Jun 30, 2024 | 861,000.00 |
| Jun 30, 2024 | 861,000.00 |
| Mar 31, 2024 | 237,000.00 |
| Mar 31, 2024 | 237,000.00 |